GW hopes to go higher on Nasdaq

21 Mar 2013

AIM-listed GW Pharmaceuticals, a £72m market capitalisation British firm that makes drugs from cannabinoids, is to list American depositary shares in the US, as the company’s London share price continues to slide.

The company has applied to the SEC for permission to list on NASDAQ.

Lazard Capital Markets and Cowen and Company are joint bookrunning managers. Canaccord Genuity is co-lead manager and Roth Capital Partners is co-manager.

GW Pharma’s shares have fallen over 40% over the last year, despite increases in profits ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial